

Regd. Office :
1506, Chiranjiv Tower,
43, Nehru Place, New Delhi-110019
CIN No. : L74899DL1993PLC056594

Tel. : 011 - 47589500, 41608929
Tel. : 011 - 21800032
Fax : 011 - 26213081
Web : www.medicamen.com

Ref: STEX/RESULTS/March-2016-17

Date: 30th May, 2016

The Bombay Stock Exchange Ltd.
25th Floor, Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Company Number: 531146

Sub. : Submission of Quarterly & Annual Results in compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015

Dear Sir,

The Board of Directors at their Meeting held today adopted the Audited Financial Results for the year & quarter ending on 31st March, 2016. The copy of the results is enclosed herewith pursuant to Regulation 33 of SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015.

The said results have been reviewed by Audit Committee along with the standalone Audit report issued by the Statutory Auditors enclosed herewith.

The Board Meeting Commenced at 11.45 a.m. and concluded at 4.15 p.m.

Kindly acknowledge the receipt.

Thanking You.

Yours truly,
For MEDICAMEN Biotech Limited


(RAHUL BISHNOI)
DIRECTOR
DIN: 00317960



Encl: As above.

MEDICAMEN Biotech Limited



Regd. Office :
1506, Chiranjiv Tower,
43, Nehru Place, New Delhi-110019
CIN No. : L74899DL1993PLC056594

Tel. : 011 - 47589500, 41608929
Tel. : 011 - 21800032
Fax : 011 - 26213081
Web : www.medicamen.com

Audited Financial Results for the Year ended 31st March 2016					
PART I			(Rupees in Lacs)		
Particulars	Quarter Ended			Year Ended	
	3 Months Ended 31/03/2016 Audited	Preceding 3 Months Ended 31/12/2015 Unaudited	Corresponding 3 Months Ended 31/03/2015 Audited	Year Ended 31/03/2016 Audited	Year Ended 31/03/2015 Audited
01. Income from operations					
(a) Net Sales/Income from operations (Net of excise duty)	1798.35	1412.01	1857.03	6727.59	7779.38
(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00
(c) Total Income from Operations (Net)	1798.35	1412.01	1857.03	6727.59	7779.38
02. Expenses					
(a) Cost of Material Consumed	1081.17	684.59	1251.89	4103.70	4903.03
(b) Purchase of Goods Traded	21.97	12.70	18.73	75.04	305.37
(c) Changes in inventory of Finished Goods and Work-in-Progress	(82.47)	226.80	(23.34)	102.08	(33.01)
(d) Employees Benefits Expenses	81.08	164.15	168.81	573.89	643.39
(e) Depreciation & Amortisation Expenses	48.17	47.50	52.04	189.69	209.67
(f) Other expenses	352.38	362.67	344.47	1371.90	1567.55
TOTAL EXPENSES	1502.30	1498.41	1812.60	6416.29	7596.00
03. Profit/(Loss) from Operations before Other Income, Finance Cost & Exceptional Items (1-2)	296.05	(86.39)	44.43	311.30	183.38
04. Other Income	5.21	8.28	14.18	70.03	110.04
05. Profit/(Loss) from ordinary activities before Finance Cost & Exceptional Items (3+4)	301.26	(78.11)	58.61	381.32	293.42
06. Finance Cost	85.01	72.92	81.87	310.14	281.33
07. Profit/(Loss) from ordinary activities after Finance Cost but before Exceptional Items (5-6)	216.25	(151.03)	(23.26)	71.19	12.09
08. Exceptional Items	0.00	0.00	0.00	0.00	0.00
09. Profit/(Loss) from Ordinary Activities before tax (7+8)	216.25	(151.03)	(23.26)	71.19	12.09
10. Tax Expenses					
Current Year	14.36	(1.14)	(4.43)	14.36	2.30
Tax Related to Earlier Year	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liability	20.16	(3.95)	(19.41)	8.73	(34.27)
11. Net Profit/(Loss) from Ordinary Activities After Tax (9-10)	181.72	(145.94)	0.59	48.09	44.06
12. Extraordinary Items (Net of Tax expenses)	-	-	-	-	-
13. Net Profit/(Loss) for the period (11-12)	181.72	(145.94)	0.59	48.09	44.06
14. Paid-up equity share capital (Rs.10/- per share)	999.36	999.36	951.13	999.36	951.13
15. Reserve excluding revaluation reserves					
16. Earning Per Share before & after Extra Ordinary Items (Rs.) (not annualised)					
(a) Basic	1.83	(1.47)	0.01	0.48	0.49
(b) Diluted	1.83	(1.47)	0.01	0.48	0.49



Works: SP-1192A & B PHASE-IV, INDUSTRIAL AREA, BHIWADI-301019 DISTT. ALWAR, BHIWADI (RAJASTHAN)
Tel. : 01493-221291, 221292, Fax : 01493-221948
PLOT No. : 86 & 87, SECTOR-6A, IIE, SIDCUL, BHEL, RANIPUR, HARIDWAR - 249403, UTTARAKHAND
Tel. : 01334-239488, 239489, Fax : 01334-239490

STATEMENT OF ASSETS & LIABILITIES			
	Particulars	As At	
		31/03/2016 Audited	31/03/2015 Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' Fund		
	(a) Share Capital	999.36	951.13
	(b) Reserves and Surplus	791.52	738.61
	(c) Money Received against Share Warrants	0.00	28.72
		1790.88	1718.46
2	Non-current Liabilities		
	(a) Long-term borrowings	351.53	458.98
	(b) Deferred Tax liabilities (Net)	74.19	65.46
	(d) Long-term Provisions	60.90	149.09
		486.62	673.52
3	Current Liabilities		
	(a) Short term borrowings	1475.96	1556.00
	(b) Trade payables	1875.71	2652.47
	(c) Other current liabilities	319.53	253.94
	(d) Short term provisions	53.09	11.86
		3724.29	4474.28
	TOTAL- EQUITY AND LIABILITIES	6001.80	6866.26
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets		
	(i) Tangible assets	1907.18	1979.66
	(ii) Intangible assets	3.07	3.97
	(iii) Capital work-in-progress	0.00	0.00
	(b) Long-term loans and advances	32.01	31.78
		1942.26	2015.42
2	Current assets		
	(a) Current investments	2.00	2.00
	(b) Inventories	1113.76	1346.36
	(c) Trade receivables	1609.37	2651.43
	(d) Cash and Bank Balances	271.60	229.40
	(e) Short-term loans and advances	851.47	450.13
	(f) Other current assets	211.34	171.53
		4059.54	4850.85
	TOTAL ASSETS	6001.80	6866.26
	NOTES :		
	<p>1. The above results after being reviewed by the Audit Committee were taken on record by the Board at its Meeting held on 30th May, 2016.</p> <p>2. The figures are regrouped in previous year also, wherever considered necessary.</p> <p>3. The company operates in single segment, viz. Pharmaceutical Formulations.</p> <p>4. The Statutory auditors of the Company have audited the above results under Regulations 33 of SEBI (LODR) Regulations, 2015</p>		
	<p>For & on behalf of Medicamen Biotech Limited</p> <p><i>R. Bishnoi</i> (Rahul Bishnoi) Chairman</p> <p>Place: Delhi Date: 30.05.2016</p>		



ASHOK SHARMA & ASSOCIATES

CHARTERED ACCOUNTANTS

311, "DEEPSHIKHA",
RAJENDRA PLACE,
NEW DELHI - 110 008
Email : casharmaashok@gmail.com
TEL:011- 25769764

Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of **Medicamen Biotech Limited**

We have audited the quarterly financial results of **Medicamen Biotech Limited** for the quarter ended 31st March, 2016 and the year to date results for the period 01.04.2015 to 31.03.2016 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31-03-2016 as well as the year to date results for the period from 01.04.2015 to 31.03.2016





Date: 30.05.2016
Place: Delhi

For Ashok Sharma & Associates
Chartered Accountants



Amit Kumar
Partner
M. No. 500805

FORM A
(for audit report with unmodified opinion)

Name of the company	Medicamen Biotech Limited
Annual financial statements for the year ended	31 st March 2016
Type of Audit observation	Un Modified / Emphasis of Matter
Frequency of observation	Whether appeared first time...../ repetitive...../ since how long period
To be signed by-	
CEO/MD	 Rajesh Madan
CFO	 Himanshu Bansal
Auditor of the Company	 Amit Kumar (partner Ashok Sharma & Associates)
Audit Committee Chairman	 Harish Rande

